Wessolly, Michael
Stephan-Falkenau, Susann
Streubel, Anna
Wiesweg, Marcel
Borchert, Sabrina
Mairinger, Elena
Kollmeier, Jens
Reis, Henning
Bauer, Torsten
Schmid, Kurt Werner
Mairinger, Thomas
Schuler, Martin
Mairinger, Fabian D.
Funding for this research was provided by:
Universitätsklinikum Essen
Article History
Received: 24 February 2021
Accepted: 14 December 2021
First Online: 7 January 2022
Declarations
:
: The study was conducted retrospectively and was approved by the Ethics Committee of the Medical Faculty of the University Duisburg-Essen (identifier: 13-5382-BO). The investigations conform to the principles of the declaration of Helsinki. All patient data were anonymized to make sure that their identity cannot be assumed. The Ethics Committee of the Medical Faculty of the University Duisburg-Essen waived the need for a written, informed consent as it was no longer necessary duo most patients being deceased at the time of data collection. Furthermore, it was no longer possible to obtain the consent retrospectively, as all patient data have been anonymized.
: Not applicable.
: Marcel Wiesweg reports honoraria from Boehringer Ingelheim, Novartis, Roche and Takeda and research funding from Bristol Myers Squibb and Takeda. Jens Kollmeier reports a consulting and advisory role without personal honoraria for Roche, Boehringer Ingelheim, Bristol Myers Squibb, MSD and Takeda. Henning Reis reports a consulting and advisory role for Bristol Myers Squibb; honoraria from Roche and Bristol Myers Squibb; travel support from Philips, Roche and Bristol Myers Squibb; research funding from Bristol Myers Squibb and share ownership from Bayer. Martin Schuler reports consultancy for AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), Lilly and Novartis; honoraria for CME presentations from Alexion, Boehringer Ingelheim, Celgene, GlaxoSmithKline, Lilly and Novartis; research funding to the institution from Boehringer Ingelheim, Bristol Myers Squibb and Novartis and other support from Universität Duisburg-Essen (patents). All remaining authors declare no conflict of interest.